Entero Therapeutics, Inc. (ENTO)

NASDAQ: ENTO · IEX Real-Time Price · USD
+0.020 (2.02%)
Jul 19, 2024, 11:47 AM EDT - Market open
Market Cap 2.50M
Revenue (ttm) n/a
Net Income (ttm) -6.44M
Shares Out 2.48M
EPS (ttm) -31.10
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 11,454
Open 1.000
Previous Close 0.990
Day's Range 1.000 - 1.040
52-Week Range 0.917 - 22.200
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Aug 20, 2024

About ENTO

Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company’s pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis. It is also involved in the deve... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Oct 11, 2016
Employees 9
Stock Exchange NASDAQ
Ticker Symbol ENTO
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements


Entero Therapeutics Announces Peer-Reviewed Publication Unveiling Novel Algorithm for Measuring Intestinal Damage in Celiac Disease

New VCIEL scale provides a more sensitive and quantitative metric of small intestinal health for monitoring Celiac Disease severity and treatment efficacy

22 days ago - GlobeNewsWire

Entero Therapeutics to Present Corporate Update at 2024 BIO International Convention

Late clinical-stage company to provide update on Phase 3 treatment for celiac disease Late clinical-stage company to provide update on Phase 3 treatment for celiac disease

2 months ago - GlobeNewsWire

Entero Therapeutics Presents Two Posters on Celiac Disease Research at the 2024 Digestive Disease Week (DDW) Conference

Presentations highlight new VCIEL scale to measure small intestinal mucosal health and research from rich database of latiglutenase Phase 2 clinical trials Presentations highlight new VCIEL scale to m...

2 months ago - GlobeNewsWire